Dr. Kevin Pauza was recently interviewed by Alan Condon of Becker’s Spine Review on the latest advancements in spine medicine and what treatments he believes are the future of the field.
In the interview, Dr. Pauza discusses his thoughts and experience with biologics for the spine, why he believes patients and payers are gravitating toward regenerative medicine rather than surgery, and his evaluation of new regenerative technologies.
Dr. Pauza also describes his current research into other manners of using Fibrin, an FDA-approved substance that is used off-label in the Discseel® Procedure, in the treatment of degenerated and herniated discs, as well as another study with the goal of proving whether fibrin can be used to eliminate recurrent disc herniations and degeneration.
Click here to read the full article from Becker’s Spine Review
Becker’s Healthcare is a prominent source for business and legal information for healthcare industry leaders with a portfolio made up of 5 industry-leading trade publications, including Becker’s Spine Review. This review features news and analysis of business and legal issues relating to spine practices.
